Vascular Smooth Muscle Cells in Cerebral Aneurysm Pathogenesis

Translational Stroke Research

Volumn 5, Issue 3, 2014, Pages 338-346

  Starke, Robert M ^a   Chalouhi, Nohra ^b   Ding, Dale ^a   Raper, Daniel M S ^a   Mckisic, M Sean ^a   Owens, Gary K ^a   Hasan, David M ^c   Medel, Ricky ^d   Dumont, Aaron S ^d  

^a UNIVERSITY OF VIRGINIA   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d TULANE UNIVERSITY   (United States)

Author keywords

Aneurysm; Cells; Inflammation; Smooth muscle; Subarachnoid hemorrhage

Indexed keywords

FERUMOXYTOL; INFLIXIMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ANEURYSM RUPTURE; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL INJURY; BRAIN ARTERY ANEURYSM; HUMAN; NERVE CELL PLASTICITY; NONHUMAN; PATHOPHYSIOLOGY; PERIPHERAL VASCULAR DISEASE; PHENOTYPE; PRIORITY JOURNAL; VASCULAR SMOOTH MUSCLE; ANIMAL; INFLAMMATION; INTRACRANIAL ANEURYSM; METABOLISM; PATHOLOGY; SMOOTH MUSCLE FIBER;

ANIMALS; ATHEROSCLEROSIS; HUMANS; INFLAMMATION; INTRACRANIAL ANEURYSM; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE;

EID: 84901187801     PISSN: 18684483     EISSN: 1868601X     Source Type: Journal    
DOI: 10.1007/s12975-013-0290-1     Document Type: Article

References (89)

1. Owens GK. Molecular control of vascular smooth muscle cell differentiation and phenotypic plasticity. Novartis Found Symp. 2007;283: 174-91. discussion 91-3, 238-41.
2. Alexander MR, Owens GK. Epigenetic control of smooth muscle cell differentiation and phenotypic switching in vascular development and disease. Annu Rev Physiol. 2012;74: 13-40. doi: 10. 1146/annurev-physiol-012110-142315.
3. Ali MS, Starke RM, Jabbour PM, Tjoumakaris SI, Gonzalez LF, Rosenwasser RH, et al. TNF-alpha induces phenotypic modulation in cerebral vascular smooth muscle cells: implications for cerebral aneurysm pathology. J Cereb Blood Flow Metab. 2013. doi: 10. 1038/jcbfm. 2013. 109.
4. Gomez D, Owens GK. Smooth muscle cell phenotypic switching in atherosclerosis. Cardiovasc Res. 2012;95(2): 156-64. doi: 10. 1093/cvr/cvs115.
5. Owens GK, Kumar MS, Wamhoff BR. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev. 2004;84(3): 767-801. doi: 10. 1152/physrev. 00041. 2003.
6. Rinkel GJ. Natural history, epidemiology and screening of unruptured intracranial aneurysms. J Neuroradiol. 2008;35(2): 99-103.
7. Komotar RJ, Zacharia BE, Mocco J, Connolly Jr ES. Controversies in the surgical treatment of ruptured intracranial aneurysms: the First Annual J. Lawrence Pool Memorial Research Symposium-controversies in the management of cerebral aneurysms. Neurosurgery. 2008;62(2): 396-407.
8. van Gijn J, Kerr RS, Rinkel GJ. Subarachnoid haemorrhage. Lancet. 2007;369(9558): 306-18.
9. Kassell NF, Torner JC. The International Cooperative Study on Timing of Aneurysm Surgery-an update. Stroke. 1984;15(3): 566-70.
10. Schievink WI. Intracranial aneurysms. N Engl J Med. 1997;336(1): 28-40.
11. Ronkainen A, Miettinen H, Karkola K, Papinaho S, Vanninen R, Puranen M, et al. Risk of harboring an unruptured intracranial aneurysm. Stroke. 1998;29(2): 359-62.
12. Laidlaw JD, Siu KH. Ultra-early surgery for aneurysmal subarachnoid hemorrhage: outcomes for a consecutive series of 391 patients not selected by grade or age. J Neurosurg. 2002;97(2): 250-8. doi: 10. 3171/jns. 2002. 97. 2. 0250. discussion 47-9.
13. Hop JW, Rinkel GJ, Algra A, van Gijn J. Quality of life in patients and partners after aneurysmal subarachnoid hemorrhage. Stroke. 1998;29(4): 798-804.
14. Ropper AH, Zervas NT. Outcome 1 year after SAH from cerebral aneurysm. Management morbidity, mortality, and functional status in 112 consecutive good-risk patients. J Neurosurg. 1984;60(5): 909-15.
15. Nieuwkamp DJ, Setz LE, Algra A, Linn FH, de Rooij NK, Rinkel GJ. Changes in case fatality of aneurysmal subarachnoid haemorrhage over time, according to age, sex, and region: a meta-analysis. Lancet Neurol. 2009;8(7): 635-42. doi: 10. 1016/S1474-4422(09)70126-7.
16. Rosenorn J, Eskesen V, Schmidt K, Espersen JO, Haase J, Harmsen A, et al. Clinical features and outcome in 1076 patients with ruptured intracranial saccular aneurysms: a prospective consecutive study. Br J Neurosurg. 1987;1(1): 33-45.
17. Saveland H, Sonesson B, Ljunggren B, Brandt L, Uski T, Zygmunt S, et al. Outcome evaluation following subarachnoid hemorrhage. J Neurosurg. 1986;64(2): 191-6.
18. Molyneux AJ, Kerr RS, Yu LM, Clarke M, Sneade M, Yarnold JA, et al. International subarachnoid aneurysm trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: a randomised comparison of effects on survival, dependency, seizures, rebleeding, subgroups, and aneurysm occlusion. Lancet. 2005;366(9488): 809-17. doi: 10. 1016/S0140-6736(05)67214-5.
19. Wiebers DO, Whisnant JP, Huston 3rd J, Meissner I, Brown Jr RD, Piepgras DG, et al. Unruptured intracranial aneurysms: natural history, clinical outcome, and risks of surgical and endovascular treatment. Lancet. 2003;362(9378): 103-10.
20. Chalouhi N, Ali MS, Jabbour PM, Tjoumakaris SI, Gonzalez LF, Rosenwasser RH, et al. Biology of intracranial aneurysms: role of inflammation. J Cereb Blood Flow Metab. 2012;32(9): 1659-76. doi: 10. 1038/jcbfm. 2012. 84.
21. Hungerford JE, Little CD. Developmental biology of the vascular smooth muscle cell: building a multilayered vessel wall. J Vasc Res. 1999;36(1): 2-27.
22. Gabbiani G, Schmid E, Winter S, Chaponnier C, de Ckhastonay C, Vandekerckhove J, et al. Vascular smooth muscle cells differ from other smooth muscle cells: predominance of vimentin filaments and a specific alpha-type actin. Proc Natl Acad Sci U S A. 1981;78(1): 298-302.
23. Babij P, Kelly C, Periasamy M. Characterization of a mammalian smooth muscle myosin heavy-chain gene: complete nucleotide and protein coding sequence and analysis of the 5′ end of the gene. Proc Natl Acad Sci U S A. 1991;88(23): 10676-80.
24. Duband JL, Gimona M, Scatena M, Sartore S, Small JV. Calponin and SM 22 as differentiation markers of smooth muscle: spatiotemporal distribution during avian embryonic development. Differentiation. 1993;55(1): 1-11.
25. van der Loop FT, Schaart G, Timmer ED, Ramaekers FC, van Eys GJ. Smoothelin, a novel cytoskeletal protein specific for smooth muscle cells. J Cell Biol. 1996;134(2): 401-11.
26. Li L, Miano JM, Cserjesi P, Olson EN. SM22 alpha, a marker of adult smooth muscle, is expressed in multiple myogenic lineages during embryogenesis. Circ Res. 1996;78(2): 188-95.
27. Caplice NM, Bunch TJ, Stalboerger PG, Wang S, Simper D, Miller DV, et al. Smooth muscle cells in human coronary atherosclerosis can originate from cells administered at marrow transplantation. Proc Natl Acad Sci U S A. 2003;100(8): 4754-9. doi: 10. 1073/pnas. 0730743100.
28. Stewart HJ, Guildford AL, Lawrence-Watt DJ, Santin M. Substrate-induced phenotypical change of monocytes/macrophages into myofibroblast-like cells: a new insight into the mechanism of in-stent restenosis. J Biomed Mater Res A. 2009;90(2): 465-71. doi: 10. 1002/jbm. a. 32100.
29. Martin K, Weiss S, Metharom P, Schmeckpeper J, Hynes B, O'Sullivan J, et al. Thrombin stimulates smooth muscle cell differentiation from peripheral blood mononuclear cells via protease-activated receptor-1, RhoA, and myocardin. Circ Res. 2009;105(3): 214-8. doi: 10. 1161/CIRCRESAHA. 109. 199984.
30. Andreeva ER, Pugach IM, Orekhov AN. Subendothelial smooth muscle cells of human aorta express macrophage antigen in situ and in vitro. Atherosclerosis. 1997;135(1): 19-27.
31. Rong JX, Shapiro M, Trogan E, Fisher EA. Transdifferentiation of mouse aortic smooth muscle cells to a macrophage-like state after cholesterol loading. Proc Natl Acad Sci U S A. 2003;100(23): 13531-6. doi: 10. 1073/pnas. 1735526100.
32. Gomez D, Owens GK. Smooth muscle cell phenotypic switching in atherosclerosis. Cardiovasc Res. 2012. doi: 10. 1093/cvr/cvs115.
33. Lee RT, Libby P. The unstable atheroma. Arterioscler Thromb Vasc Biol. 1997;17(10): 1859-67.
34. Falk E. Why do plaques rupture? Circulation. 1992;86(6 Suppl): III30-42.
35. Owens GK. Molecular control of vascular smooth muscle cell differentiation. Acta Physiol Scand. 1998;164(4): 623-35.
36. McDonald OG, Wamhoff BR, Hoofnagle MH, Owens GK. Control of SRF binding to CArG box chromatin regulates smooth muscle gene expression in vivo. J Clin Invest. 2006;116(1): 36-48. doi: 10. 1172/JCI26505.
37. Sano H, Sudo T, Yokode M, Murayama T, Kataoka H, Takakura N, et al. Functional blockade of platelet-derived growth factor receptor-beta but not of receptor-alpha prevents vascular smooth muscle cell accumulation in fibrous cap lesions in apolipoprotein E-deficient mice. Circulation. 2001;103(24): 2955-60.
38. Jawien A, Bowen-Pope DF, Lindner V, Schwartz SM, Clowes AW. Platelet-derived growth factor promotes smooth muscle migration and intimal thickening in a rat model of balloon angioplasty. J Clin Invest. 1992;89(2): 507-11. doi: 10. 1172/JCI115613.
39. Amento EP, Ehsani N, Palmer H, Libby P. Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. Arterioscler Thromb. 1991;11(5): 1223-30.
40. Johnstone SR, Ross J, Rizzo MJ, Straub AC, Lampe PD, Leitinger N, et al. Oxidized phospholipid species promote in vivo differential cx43 phosphorylation and vascular smooth muscle cell proliferation. Am J Pathol. 2009;175(2): 916-24. doi: 10. 2353/ajpath. 2009. 090160.
41. Couffinhal T, Duplaa C, Moreau C, Lamaziere JM, Bonnet J. Regulation of vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 in human vascular smooth muscle cells. Circ Res. 1994;74(2): 225-34.
42. Loppnow H, Libby P. Proliferating or interleukin 1-activated human vascular smooth muscle cells secrete copious interleukin 6. J Clin Invest. 1990;85(3): 731-8. doi: 10. 1172/JCI114498.
43. Fabunmi RP, Baker AH, Murray EJ, Booth RF, Newby AC. Divergent regulation by growth factors and cytokines of 95 kDa and 72 kDa gelatinases and tissue inhibitors or metalloproteinases-1, -2, and -3 in rabbit aortic smooth muscle cells. Biochem J. 1996;315(Pt 1): 335-42.
44. Speer MY, Yang HY, Brabb T, Leaf E, Look A, Lin WL, et al. Smooth muscle cells give rise to osteochondrogenic precursors and chondrocytes in calcifying arteries. Circ Res. 2009;104(6): 733-41. doi: 10. 1161/CIRCRESAHA. 108. 183053.
45. Jiang J, Chan YS, Loh YH, Cai J, Tong GQ, Lim CA, et al. A core Klf circuitry regulates self-renewal of embryonic stem cells. Nat Cell Biol. 2008;10(3): 353-60. doi: 10. 1038/ncb1698.
46. Wernig M, Meissner A, Foreman R, Brambrink T, Ku M, Hochedlinger K, et al. In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature. 2007;448(7151): 318-24. doi: 10. 1038/nature05944.
47. Yoshida T, Kaestner KH, Owens GK. Conditional deletion of Kruppel-like factor 4 delays downregulation of smooth muscle cell differentiation markers but accelerates neointimal formation following vascular injury. Circ Res. 2008;102(12): 1548-57. doi: 10. 1161/CIRCRESAHA. 108. 176974.
48. Wamhoff BR, Hoofnagle MH, Burns A, Sinha S, McDonald OG, Owens GK. A G/C element mediates repression of the SM22alpha promoter within phenotypically modulated smooth muscle cells in experimental atherosclerosis. Circ Res. 2004;95(10): 981-8. doi: 10. 1161/01. RES. 0000147961. 09840. fb.
49. Salmon M, Gomez D, Greene E, Shankman L, Owens GK. Cooperative binding of KLF4, pELK-1, and HDAC2 to a G/C repressor element in the SM22alpha promoter mediates transcriptional silencing during SMC phenotypic switching in vivo. Circ Res. 2012;111(6): 685-96. doi: 10. 1161/CIRCRESAHA. 112. 269811.
50. Starke RM, Chalouhi N, Ali MS, Jabbour PM, Tjoumakaris SI, Gonzalez LF, et al. The role of oxidative stress in cerebral aneurysm formation and rupture. Curr Neurovasc Res. 2013;10(3): 247-55.
51. Alfano JM, Kolega J, Natarajan SK, Xiang J, Paluch RA, Levy EI, et al. Intracranial aneurysms occur more frequently at bifurcation sites that typically experience higher hemodynamic stresses. Neurosurgery. 2013. doi: 10. 1227/NEU. 0000000000000016.
52. Kolega J, Gao L, Mandelbaum M, Mocco J, Siddiqui AH, Natarajan SK, et al. Cellular and molecular responses of the basilar terminus to hemodynamics during intracranial aneurysm initiation in a rabbit model. J Vasc Res. 2011;48(5): 429-42. doi: 10. 1159/000324840.
53. Aoki T, Kataoka H, Nishimura M, Ishibashi R, Morishita R, Miyamoto S. Ets-1 promotes the progression of cerebral aneurysm by inducing the expression of MCP-1 in vascular smooth muscle cells. Gene Ther. 2010;17(9): 1117-23. doi: 10. 1038/gt. 2010. 60.
54. Bygglin H, Laaksamo E, Myllarniemi M, Tulamo R, Hernesniemi J, Niemela M, et al. Isolation, culture, and characterization of smooth muscle cells from human intracranial aneurysms. Acta Neurochir (Wien). 2011;153(2): 311-8. doi: 10. 1007/s00701-010-0836-x.
55. Chalouhi N, Ali MS, Starke RM, Jabbour PM, Tjoumakaris SI, Gonzalez LF, et al. Cigarette smoke and inflammation: role in cerebral aneurysm formation and rupture. Mediators Inflamm. 2012;2012: 271582. doi: 10. 1155/2012/271582.
56. Kosierkiewicz TA, Factor SM, Dickson DW. Immunocytochemical studies of atherosclerotic lesions of cerebral berry aneurysms. J Neuropathol Exp Neurol. 1994;53(4): 399-406.
57. Frosen J, Marjamaa J, Myllarniemi M, Abo-Ramadan U, Tulamo R, Niemela M, et al. Contribution of mural and bone marrow-derived neointimal cells to thrombus organization and wall remodeling in a microsurgical murine saccular aneurysm model. Neurosurgery. 2006;58(5): 936-44. doi: 10. 1227/01. NEU. 0000210260. 55124. A4. discussion -44.
58. Starke RM, Ali M, Jabbour P, Tjoumakaris SI, Gonzalez LF, Hasan D, et al. Cigarette smoke modulates vascular smooth muscle phenotype: implications for carotid and cerebrovascular disease. Plos One. 2013;8(8): e71954. doi: 10. 1371/journal. pone. 0071954.
59. Nakajima N, Nagahiro S, Sano T, Satomi J, Satoh K. Phenotypic modulation of smooth muscle cells in human cerebral aneurysmal walls. Acta Neuropathol. 2000;100(5): 475-80.
60. Kilic T, Sohrabifar M, Kurtkaya O, Yildirim O, Elmaci I, Gunel M, et al. Expression of structural proteins and angiogenic factors in normal arterial and unruptured and ruptured aneurysm walls. Neurosurgery. 2005;57(5): 997-1007. discussion 997.
61. Pera J, Korostynski M, Krzyszkowski T, Czopek J, Slowik A, Dziedzic T, et al. Gene expression profiles in human ruptured and unruptured intracranial aneurysms: what is the role of inflammation? Stroke. 2010;41(2): 224-31. doi: 10. 1161/STROKEAHA. 109. 562009.
62. Sibon I, Mercier N, Darret D, Lacolley P, Lamaziere JM. Association between semicarbazide-sensitive amine oxidase, a regulator of the glucose transporter, and elastic lamellae thinning during experimental cerebral aneurysm development: laboratory investigation. J Neurosurg. 2008;108(3): 558-66. doi: 10. 3171/jns/2008/108/3/0558.
63. Merei FT, Gallyas F. Role of the structural elements of the arterial wall in the formation and growth of intracranial saccular aneurysms. Neurol Res. 1980;2(3-4): 283-303.
64. Coucke PJ, Willaert A, Wessels MW, Callewaert B, Zoppi N, De Backer J, et al. Mutations in the facilitative glucose transporter GLUT10 alter angiogenesis and cause arterial tortuosity syndrome. Nat Genet. 2006;38(4): 452-7. doi: 10. 1038/ng1764.
65. Ali MS, Starke RM, Jabbour P, Tjoumakaris SI, Gonzalez LF, Rosenwasser RH, et al. 184 Infliximab suppresses TNF-alpha induced inflammatory phenotype in cerebral vascular smooth muscle cells: implications for cerebral aneurysm formation. Neurosurgery. 2013;60 Suppl 1: 181. doi: 10. 1227/01. neu. 0000432774. 35977. 11.
66. Chalouhi N, Points L, Pierce GL, Ballas Z, Jabbour P, Hasan D. Localized increase of chemokines in the lumen of human cerebral aneurysms. Stroke. 2013. doi: 10. 1161/STROKEAHA. 113. 002361.
67. Aoki T, Kataoka H, Ishibashi R, Nozaki K, Egashira K, Hashimoto N. Impact of monocyte chemoattractant protein-1 deficiency on cerebral aneurysm formation. Stroke. 2009;40(3): 942-51. doi: 10. 1161/STROKEAHA. 108. 532556.
68. Aoki T, Kataoka H, Ishibashi R, Nozaki K, Morishita R, Hashimoto N. Reduced collagen biosynthesis is the hallmark of cerebral aneurysm: contribution of interleukin-1beta and nuclear factor-kappaB. Arterioscler Thromb Vasc Biol. 2009;29(7): 1080-6. doi: 10. 1161/ATVBAHA. 108. 180760.
69. Aoki T, Kataoka H, Shimamura M, Nakagami H, Wakayama K, Moriwaki T, et al. NF-kappaB is a key mediator of cerebral aneurysm formation. Circulation. 2007;116(24): 2830-40. doi: 10. 1161/CIRCULATIONAHA. 107. 728303.
70. Kim SC, Singh M, Huang J, Prestigiacomo CJ, Winfree CJ, Solomon RA, et al. Matrix metalloproteinase-9 in cerebral aneurysms. Neurosurgery. 1997;41(3): 642-66. discussion 6-7.
71. Aoki T, Kataoka H, Morimoto M, Nozaki K, Hashimoto N. Macrophage-derived matrix metalloproteinase-2 and -9 promote the progression of cerebral aneurysms in rats. Stroke. 2007;38(1): 162-9. doi: 10. 1161/01. STR. 0000252129. 18605. c8.
72. Moriwaki T, Takagi Y, Sadamasa N, Aoki T, Nozaki K, Hashimoto N. Impaired progression of cerebral aneurysms in interleukin-1beta-deficient mice. Stroke. 2006;37(3): 900-5. doi: 10. 1161/01. STR. 0000204028. 39783. d9.
73. Fukuda S, Hashimoto N, Naritomi H, Nagata I, Nozaki K, Kondo S, et al. Prevention of rat cerebral aneurysm formation by inhibition of nitric oxide synthase. Circulation. 2000;101(21): 2532-8.
74. Jayaraman T, Berenstein V, Li X, Mayer J, Silane M, Shin YS, et al. Tumor necrosis factor alpha is a key modulator of inflammation in cerebral aneurysms. Neurosurgery. 2005;57(3): 558-64. discussion -64.
75. Sakaki T, Kohmura E, Kishiguchi T, Yuguchi T, Yamashita T, Hayakawa T. Loss and apoptosis of smooth muscle cells in intracranial aneurysms. Studies with in situ DNA end labeling and antibody against single-stranded DNA. Acta Neurochir (Wien). 1997;139(5): 469-74.
76. Hara A, Yoshimi N, Mori H. Evidence for apoptosis in human intracranial aneurysms. Neurol Res. 1998;20(2): 127-30.
77. Guo F, Li Z, Song L, Han T, Feng Q, Guo Y, et al. Increased apoptosis and cysteinyl aspartate specific protease-3 gene expression in human intracranial aneurysm. J Clin Neurosci. 2007;14(6): 550-5. doi: 10. 1016/j. jocn. 2005. 11. 018.
78. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131(5): 861-72. doi: 10. 1016/j. cell. 2007. 11. 019.
79. Frosen J, Tulamo R, Paetau A, Laaksamo E, Korja M, Laakso A, et al. Saccular intracranial aneurysm: pathology and mechanisms. Acta Neuropathol. 2012;123(6): 773-86. doi: 10. 1007/s00401-011-0939-3.
80. Vlak MH, Algra A, Brandenburg R, Rinkel GJ. Prevalence of unruptured intracranial aneurysms, with emphasis on sex, age, comorbidity, country, and time period: a systematic review and meta-analysis. Lancet Neurol. 2011;10(7): 626-36. doi: 10. 1016/S1474-4422(11)70109-0.
81. Vlak MH, Rinkel GJ, Greebe P, Algra A. Independent risk factors for intracranial aneurysms and their joint effect: a case-control study. Stroke. 2013;44(4): 984-7. doi: 10. 1161/STROKEAHA. 111. 000329.
82. Gerzanich V, Zhang F, West GA, Simard JM. Chronic nicotine alters NO signaling of Ca(2+) channels in cerebral arterioles. Circ Res. 2001;88(3): 359-65.
83. Starke RM, Chalouhi N, Ali MS, Jabbour P, Tjoumakaris SI, Gonzalez LF, et al. 190 critical role of TNF-a in cerebral aneurysm formation and rupture. Neurosurgery. 2013;60 Suppl 1: 183. doi: 10. 1227/01. neu. 0000432780. 74094. e2.
84. Faustman D, Davis M. TNF receptor 2 pathway: drug target for autoimmune diseases. Nat Rev Drug Discov. 2010;9(6): 482-93. doi: 10. 1038/nrd3030.
85. Bonilla-Hernan MG, Miranda-Carus ME, Martin-Mola E. New drugs beyond biologics in rheumatoid arthritis: the kinase inhibitors. Rheumatology (Oxford). 2013;50(9): 1542-50. doi: 10. 1093/rheumatology/ker192.
86. Hasan D, Chalouhi N, Jabbour P, Dumont AS, Kung DK, Magnotta VA, et al. Early change in ferumoxytol-enhanced magnetic resonance imaging signal suggests unstable human cerebral aneurysm: a pilot study. Stroke. 2012;43(12): 3258-65. doi: 10. 1161/STROKEAHA. 112. 673400.
87. Hasan DM, Chalouhi N, Jabbour P, Dumont AS, Kung DK, Magnotta VA, et al. Evidence that acetylsalicylic acid attenuates inflammation in the walls of human cerebral aneurysms: preliminary results. J Am Heart Assoc. 2013;2(1): e000019. doi: 10. 1161/JAHA. 112. 000019.
88. Hasan DM, Chalouhi N, Jabbour P, Magnotta VA, Kung DK, Young WL. Imaging aspirin effect on macrophages in the wall of human cerebral aneurysms using ferumoxytol-enhanced MRI: preliminary results. J Neuroradiol. 2013;40(3): 187-91. doi: 10. 1016/j. neurad. 2012. 09. 002.
89. Hasan DM, Mahaney KB, Magnotta VA, Kung DK, Lawton MT, Hashimoto T, et al. Macrophage imaging within human cerebral aneurysms wall using ferumoxytol-enhanced MRI: a pilot study. Arterioscler Thromb Vasc Biol. 2012;32(4): 1032-8. doi: 10. 1161/ATVBAHA. 111. 239871.